NRX Pharmaceuticals, Inc.(NASDAQ : NRXP)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.23%||163.01||0.7%||$1094.93m|
|MRK||Merck & Co., Inc.||0.96%||76.31||0.7%||$1034.63m|
|LLY||Eli Lilly & Co.||7.57%||233.54||1.1%||$964.38m|
|BMY||Bristol-Myers Squibb Co.||0.83%||65.80||1.0%||$630.11m|
|CNST||Constellation Pharmaceuticals, Inc.||0.27%||33.85||0.0%||$111.08m|
|RPRX||Royalty Pharma Plc||2.03%||43.05||0.2%||$106.09m|
NRX Pharmaceuticals, Inc. is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company recently announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure (the NRx COVID-19 Drug). It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior the NRx Antidepressant Drug Regimen. The company is headquartered in Wilmington, DE.